EQRX News and Press, EQRx Inc. From 08/20/23

NEW YORK, NY / ACCESSWIRE / August 20, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: New Relic, Inc. (NYSE:NEWR)'s sal...

2023-08-15 10:55:30 ET More on SoftBank investments: Sweetgreen: Waiting For A Catapult Event WeWork Inc. ( WE ) Q2 2023 Earnings Call Transcript IonQ Earnings: Surpassing Expectations, Quantum Leap In Revenue Beat T-Mobile US: Clean Capital Return Policy...

2023-08-02 12:15:04 ET Penny stocks are an interesting asset class. On any given day, you will see at least a handful experiencing extreme levels and explosive moves. Today, one of the most active cheap stocks under $5 is WaveDancer, Inc. ( NASDAQ: WAVD ). The company’s tradi...

2023-08-01 10:04:48 ET Gainers: Adamis Pharmaceuticals ( ADMP ) +71% . ABVC BioPharma ( ABVC ) +49% . EQRx ( EQRX ) +18% . Rhythm Pharmaceuticals ( RYTM ) +17% . Esperion Therapeutics ( ESPR ) +6% . Losers: TG Therapeu...

2023-08-01 08:32:02 ET A clinical-stage oncology company, Revolution Medicines ( NASDAQ: RVMD ) plans to acquire EQRx ( NASDAQ: EQRX ) in an all-stock transaction intended to add more than $1B in net cash to Revolution Medicines’ balance sheet. The deal, which...

R evolution Medicines Expect s to Conduct Late-Stage Development of RAS(ON) I nhibitor Drug C andidate Pipeline Supported by Fortified Balance Sheet Agreement is the Result of a Rigorous Process Conducted by Independe...

2023-05-19 05:00:00 ET Summary The companies parted ways after tighter approval rules made it harder to market their new drugs in the U.S. CStone partner EQRx has launched a restructuring drive and layoffs to tackle its financial woes, keeping only one drug pipeline running. A...

2023-05-14 14:20:00 ET Summary Bliss Biopharma (Hangzhou) announced it may out-license global rights (ex-China) for its HER2 ADC to Japan’s Eisai Pharma in a deal with a potential value of $2 billion. Shanghai Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to...

2023-05-09 20:29:00 ET Summary EQRx stated that it hoped to have ten drugs in ten years, and that's where I threw my hands up in the air. The company went public in 2021 (via a SPAC merger, very fashionable at the time), with a somewhat changed business model. The company went...

2023-05-08 22:57:09 ET EQRx, Inc. (EQRX) Q1 2023 Earnings Conference Call May 8, 2023 16:30 ET Company Participants Michelle Greenblatt - Head of Investor Relations Melanie Nallicheri - President & Chief Executive Officer Eric Hedrick - Chief Physician Execut...